Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASTX727 in Cancer Patients With Hepatic Impairment
NCT04953910Phase 1Recruiting
- Sponsor
- Taiho Oncology
- Start
- Dec 2022
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 1, open-label trial of inqovi in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and solid tumor (3 arms), sponsored by Taiho Oncology. Primary endpoint: 5-day Cumulative Area Under the Concentration-time Curve Within 1 Dosing Interval. Started Dec 2022; status: recruiting.
02
Drugs
inqovi
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)solid tumor
Beyond the preview
Go deeper on NCT04953910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04953910.